

26th May, 2017

The Dy. General Manager (Listing Dept.)
BSE Limited.,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

✓ The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Submission / Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), 2015, (“Listing Regulations”) of:

1. **Audited Financial Results (standalone and consolidated) for the quarter and year ended on 31st March, 2017**
2. **Declaration of Final Dividend and pay out date**
3. **Notice of Book Closure**
4. **Re-appointment of Dr. Chaitanya Dutt, Director (Research & Development) as a whole time director**
5. **Recommendation to shareholders for issuance of NCDs**

In continuation to our letter dated 11th May, 2017 intimating about the Board meeting to be held on Friday, 26th May, 2017, we would like to inform that the Board meeting commenced at 03:00 pm and concluded at 06:30 pm. The following items, inter alia, were considered and approved/ recommended by the Board:

- (a) Approved Audited Financial Results (both standalone and consolidated) of the Company along with audit report for the quarter and year ended on 31st March, 2017. The said financial results are enclosed herewith.

In terms of Regulation 47 of the Listing Regulations, the Company will publish an extract of Audited Consolidated Financial Results for the quarter and year ended on 31st March, 2017. Both Audited Standalone and Consolidated Financial Results will be available at Company's website www.torrentpharma.com.

A Press Release on Financial Results which is being submitted to the media is also enclosed herewith.

- (b) Recommended to the members a final dividend of Rs. 4 (80%) per equity share on 169,222,720 equity shares of Rs. 5 each. The final dividend amount, if declared by the Shareholders, are proposed to be paid / dispatched on or around 4th August, 2017. Earlier an interim dividend of Rs. 10/- per equity share was paid during the last quarter.

Pursuant to Regulation 42 of the Listing Regulations, this is to inform that the Share Transfer Books and Register of Members of the Company will remain closed from 21st June, 2017 to 23rd June, 2017 (both days inclusive) for the purpose of deciding the name of shareholders entitled for final dividend for the year ended 31st March, 2017, if declared by the shareholders at the ensuing Annual General Meeting ("AGM").

- (c) Approved the re-appointment of Dr. Chaitanya Dutt, Director (Research & Development) as a whole-time director for a period of 3 years commencing from 1st January, 2018 subject to the approval of the members.
- (d) Recommended to the members to obtain enabling approval for issuance of Redeemable Non-Convertible debentures/ Bonds by way of private placement for an amount not exceeding Rs. 7500 crores.

The copy of the AGM Notice on the aforesaid proposal will be sent to the exchange in due course, prior to dispatch of the same to the shareholders.

The above is for your information and record.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL
VP (LEGAL) & COMPANY SECRETARY

Encl.: A/a